Samuel A. Hamood - 13 Jun 2022 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Reporting relationship: Director
Issuer ticker: FNCH
Reported as of: 13 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2022, 17:05:48 UTC
Prior SEC filing: 26 May 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Joseph Vittiglio, Attorney-in-Fact

Key filing fact

Samuel A. Hamood filed Form 4 for Finch Therapeutics Group, Inc. (FNCH) on 15 Jun 2022.

Key facts

This page summarizes Samuel A. Hamood's Form 4 filing for Finch Therapeutics Group, Inc. (FNCH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2022, 17:05.

Change

Previous filing in this sequence was filed on 26 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FNCH transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +44,843
Change %
Price: $0.000000
Shares after: 44,843
Date: 13 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,843
Exercise price: $2.79
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest in twelve equal monthly installments beginning on July 13, 2022, subject to the Reporting Person continuing to provide service through each such date.